Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares of Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 243,177 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $36.23, for a total value of $8,810,302.71. Following the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at $674,991,673.97. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Up 3.1%

Shares of NASDAQ:ROIV opened at $37.37 on Wednesday. The stock has a market cap of $26.99 billion, a price-to-earnings ratio of -70.51 and a beta of 1.12. Roivant Sciences Ltd. has a 12-month low of $11.54 and a 12-month high of $37.46. The business’s 50 day moving average is $34.16 and its 200 day moving average is $30.17.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, equities research analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Leerink Partners set a $42.00 price target on shares of Roivant Sciences in a report on Thursday, May 21st. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Thursday, August 6th. Piper Sandler reiterated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, May 21st. Finally, Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $35.14.

Institutional Investors Weigh In On Roivant Sciences

Several large investors have recently made changes to their positions in ROIV. SBI Securities Co. Ltd. boosted its holdings in shares of Roivant Sciences by 1,740.3% in the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares during the last quarter. Allworth Financial LP increased its holdings in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the last quarter. Parallel Advisors LLC raised its position in Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after acquiring an additional 520 shares during the period. Kestra Advisory Services LLC bought a new stake in Roivant Sciences in the fourth quarter worth about $47,000. Finally, Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock valued at $69,000 after acquiring an additional 441 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.